Product Center
Kickoff Meeting for Phase I Clinical Trial of Freeze-Dried Human Rabies Vaccine (Human Diploid Cells) Successfully Held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-11-27
- Views:
(Summary description)Recently, the Phase I clinical trial kickoff meeting for Ab&B Bio Tech Co., Ltd. JS's freeze-dried human rabies vaccine (human diploid cells) was successfully held at the research site in Hubei Province. This cli
Kickoff Meeting for Phase I Clinical Trial of Freeze-Dried Human Rabies Vaccine (Human Diploid Cells) Successfully Held
(Summary description)Recently, the Phase I clinical trial kickoff meeting for Ab&B Bio Tech Co., Ltd. JS's freeze-dried human rabies vaccine (human diploid cells) was successfully held at the research site in Hubei Province.
This cli
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-11-27 15:19
- Views:
Recently, the Phase I clinical trial kickoff meeting for Ab&B Bio Tech Co., Ltd. JS's freeze-dried human rabies vaccine (human diploid cells) was successfully held at the research site in Hubei Province.
This clinical trial is a Phase I, randomized, single-arm study designed to evaluate the safety of the freeze-dried human rabies vaccine (human diploid cells) in participants aged 10–60 years using three immunization schedules: the five-dose Essen regimen, the 2-1-1 Zagreb regimen, and the simplified four-dose regimen.
Rabies is a severe zoonotic infectious disease. Approximately 59,000 people worldwide die from rabies each year, with 99% of cases occurring in Africa and Asia, resulting in estimated economic losses of $8.6 billion annually. China is one of the countries most affected by rabies, with approximately 40 million people exposed to animal bites each year. Vaccination remains the most effective means of rabies prevention.
In the 1880s, Louis Pasteur developed the first-generation neural tissue vaccine, which was gradually phased out due to its high rate of adverse reactions, multiple-dose immunization requirements, and suboptimal immune protection. After the 1950s, avian embryo culture vaccines were introduced, but they still exhibited relatively high adverse reaction rates and inferior immunogenicity, limiting their widespread adoption.
In 1967, the Wistar Institute pioneered the human diploid cell vaccine (HDCV) using the WI-38 cell line, which demonstrated high antibody titers, low adverse reaction rates, and excellent safety. The World Health Organization (WHO) subsequently recommended HDCV as the gold standard for human rabies vaccines.
HDCV has been used in Europe and North America for over 40 years, proving its safety and efficacy. It is commonly used as a reference vaccine in clinical trials for new rabies vaccines. The overall adverse reaction rate of HDCV is significantly lower than that of purified chick embryo cell vaccine (PCECV). Compared with purified Vero cell rabies vaccine (PVRV), HDCV shows lower rates of local pain, fever, and fatigue. Additionally, HDCV causes less local pain and fever than PCECV, demonstrating superior safety over both alternatives.
Large-scale studies in the United States, Thailand, India, Iran, and other countries have confirmed HDCV's strong immunogenicity.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groupsInfluenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
